1. Home
  2. EXEL vs ARE Comparison

EXEL vs ARE Comparison

Compare EXEL & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • ARE
  • Stock Information
  • Founded
  • EXEL 1994
  • ARE 1994
  • Country
  • EXEL United States
  • ARE United States
  • Employees
  • EXEL N/A
  • ARE N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • ARE Real Estate Investment Trusts
  • Sector
  • EXEL Health Care
  • ARE Real Estate
  • Exchange
  • EXEL Nasdaq
  • ARE Nasdaq
  • Market Cap
  • EXEL 11.1B
  • ARE 13.2B
  • IPO Year
  • EXEL 2000
  • ARE 1997
  • Fundamental
  • Price
  • EXEL $42.52
  • ARE $50.92
  • Analyst Decision
  • EXEL Buy
  • ARE Hold
  • Analyst Count
  • EXEL 24
  • ARE 9
  • Target Price
  • EXEL $44.73
  • ARE $82.43
  • AVG Volume (30 Days)
  • EXEL 3.3M
  • ARE 3.3M
  • Earning Date
  • EXEL 11-04-2025
  • ARE 10-27-2025
  • Dividend Yield
  • EXEL N/A
  • ARE 10.10%
  • EPS Growth
  • EXEL 53.55
  • ARE N/A
  • EPS
  • EXEL 2.38
  • ARE N/A
  • Revenue
  • EXEL $2,288,218,000.00
  • ARE $3,058,395,000.00
  • Revenue This Year
  • EXEL $9.14
  • ARE N/A
  • Revenue Next Year
  • EXEL $12.51
  • ARE N/A
  • P/E Ratio
  • EXEL $17.53
  • ARE N/A
  • Revenue Growth
  • EXEL 9.93
  • ARE N/A
  • 52 Week Low
  • EXEL $31.90
  • ARE $51.63
  • 52 Week High
  • EXEL $49.62
  • ARE $112.42
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 60.26
  • ARE 21.75
  • Support Level
  • EXEL $41.23
  • ARE $52.94
  • Resistance Level
  • EXEL $43.72
  • ARE $56.35
  • Average True Range (ATR)
  • EXEL 1.47
  • ARE 2.31
  • MACD
  • EXEL 0.34
  • ARE -0.16
  • Stochastic Oscillator
  • EXEL 83.81
  • ARE 0.55

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

Share on Social Networks: